Cite
Pathak S, S S, Banerjee A, et al. Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in . Oncotarget. 2017;9(7):7739-7748doi: 10.18632/oncotarget.22471.
Pathak, S., S, S., Banerjee, A., Marotta, F., Gopinath, M., Murugesan, R., Zhang, H., B, B., Girigoswami, A., Sollano, J., & Sun, X. F. (2018). Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in . Oncotarget, 9(7), 7739-7748. https://doi.org/10.18632/oncotarget.22471
Pathak, Surajit, et al. "Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in ." Oncotarget vol. 9,7 (2018): 7739-7748. doi: https://doi.org/10.18632/oncotarget.22471
Pathak S, S S, Banerjee A, Marotta F, Gopinath M, Murugesan R, Zhang H, B B, Girigoswami A, Sollano J, Sun XF. Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in . Oncotarget. 2017 Nov 16;9(7):7739-7748. doi: 10.18632/oncotarget.22471. eCollection 2018 Jan 26. PMID: 29484148; PMCID: PMC5800940.
Copy
Download .nbib